

An Emerging Role for Anti-inflammatory Agents for Chemoprevention.	1
References	4
Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia . . .	7
1 Molecular Basis of Colorectal Adenoma and Carcinoma	9
1.1 Genetic Basis of Adenoma-Carcinoma Sequence.	9
1.2 Adenomatous Polyposis Coli.	10
1.3 The Microsatellite Instability Pathway in CRC	11
1.4 The Epigenetic Pathway in CRC	12
1.5 COX-2/mPGES-1 Pathway	12
1.6 Prostaglandin Transporters in CRC	16
1.7 Epidermal Growth Factor Receptor Pathway.	16
1.8 Peroxisome Proliferator-Activated Receptors.	17
1.9 Tumor Microenvironment in Colorectal Carcinogenesis	18
2 COX-2 Gene Expression in CRC	18
2.1 Transcriptional Regulation	19
2.2 Post-transcriptional Regulation and the 3' Untranslated Region.	21
2.3 AU-Rich Elements and ARE-Binding Proteins	22
2.4 MicroRNAs	26
3 Conclusions	29
References	30
Mode of Action of Aspirin as a Chemopreventive Agent.	39
1 Introduction	41
2 Mechanisms of Action of Aspirin	42
2.1 Historical Overview of Aspirin and its Mechanism of Action (Box. 1).	42
2.2 Insights into the Mechanism of Inhibition of COXs by Aspirin.	44
3 Pharmacology/Pharmacokinetic of Aspirin	49

3.1	COX-Isozyme Selectivity in Vitro	49
3.2	Pharmacokinetic	50
3.3	Determinants of Achieved COX-Isozyme Selectivity by Clinical Doses of Aspirin.	52
4	Role of Platelets in Tumorigenesis	53
4.1	Platelet-Mediated Mechanisms in Tumorigenesis and Metastasis.	53
4.2	Role of Platelet COX-1 in Aspirin Chemoprevention.	56
5	COX-Independent Mechanisms of Aspirin Chemoprevention	57
5.1	Inhibition of NF- κ B.	57
5.2	Interruption of Extracellular Signal-Regulated Kinases	59
5.3	Induction of Apoptosis by Caspase Activation	59
5.4	Inhibition of Wnt/ β -Catenin Pathway.	59
6	Aspirin-Mediated Acetylation of Extra-COX Proteins	59
7	Conclusions	60
	References	61

Coxibs: Pharmacology, Toxicity and Efficacy

in Cancer Clinical Trials	67
1 Introduction	69
2 Pharmacology of tNSAIDs and Coxibs	76
3 Efficacy of Coxibs in CRC Chemoprevention Trials	77
4 CV Toxicity of Coxibs.	80
4.1 Risk Estimates: Data from Trials and Observational Studies.	80
4.2 Mechanisms of CV Toxicity of Coxibs	83
4.3 Ongoing Randomized Clinical Trials with Coxibs/NSAIDs.	85
5 Conclusions and Perspectives	86
References	87

COX-2 Active Agents in the Chemoprevention

of Colorectal Cancer	95
References	102

New NSAID Targets and Derivatives for Colorectal

Cancer Chemoprevention	105
1 Introduction	106
2 Targeting COX-2.	109
3 COX-Independent Targets	110
3.1 Inhibition of cGMP PDEs.	110
3.2 Generation of Reactive Oxygen Species.	112
3.3 Downregulation of Survivin	113
3.4 Other COX-Independent Targets	114
4 Conclusions	115
References	117

Aspirin in Prevention of Sporadic Colorectal Cancer:**Current Clinical Evidence and Overall Balance**

of Risks and Benefits	121
1 Introduction	122
2 Aspirin in Prevention of Colorectal Cancer.	122
2.1 Observational Studies.	122
2.2 Randomised Controlled Trials.	125
3 Effects on Other Cancers	131
4 Overall Balance of Risk and Benefit	135
5 Summary and Outstanding Issues	137
References	139

Nutritional Agents with Anti-inflammatory Properties in**Chemoprevention of Colorectal Neoplasia** 143

1 Naturally Occurring Substances Used as Pharmaceutical Preparations—‘Nutraceuticals’	144
2 Anti-inflammatory Agents for Prevention and Treatment of CRC	145
3 Anti-inflammatory Nutraceuticals with Evidence of Anti-CRC Activity.	145
3.1 Omega-3 PUFAs	145
3.2 Curcumin	149
3.3 Resveratrol	151
3.4 Other Dietary Polyphenols	152
3.5 Other Natural Anti-inflammatory Agents with CRC Chemopreventative Efficacy	152
4 Summary	153
References	153

Genetics, Inheritance and Strategies for Prevention in Populations**at High Risk of Colorectal Cancer (CRC)** 157

1 Introduction	159
2 CAPP1	163
2.1 CAPP1 Trial Design	164
2.2 CAPP1 Endpoint Ascertainments.	165
2.3 CAPP1 Laboratory and Statistical Methods.	165
2.4 CAPP1 Results	166
2.5 CAPP1 Toxicity	168
2.6 CAPP1 Conclusions.	169
3 Chemoprevention in Lynch Syndrome: CAPP2	170
3.1 CAPP2 Trial Design	172
3.2 CAPP2 Endpoint Ascertainments.	172
3.3 CAPP2 Statistical Methods.	172
3.4 CAPP2 Results	175
3.5 CAPP2 Toxicity	178
3.6 CAPP2 Discussion.	179

4	CAPP3.....	180
5	Conclusion	180
	References	181